AKL (United Kingdom)
AKL identifies and synthesizes secondary metabolites of plant origin with proven efficacy & safety. This innovative approach greatly increases the chances of success, while reducing the probability of unexpected side effects. AKL is focused on developing its lead clinical asset APPA, a novel therapeutic for inflammatory diseases where there is a high unmet need, including osteoarthritis (OA) and other complex diseases of ageing.
Basic Information
- Category: business
- Website: http://www.aklrd.com
Documented Facts
- Inception (Wikidata): 2013 (Source 2: Wikidata Q59536146, revision 2474129656)
- Country (Wikidata; date unspecified): United Kingdom (Source 2: Wikidata Q59536146, revision 2474129656; Source 3: Wikidata label: Q145, revision 2554939741)
- Official website (Wikidata; date unspecified): http://www.aklrd.com/ (Source 2: Wikidata Q59536146, revision 2474129656)
Evidence and Sources
- AKL (United Kingdom) — Official Website (official)
- Wikidata Q59536146, revision 2474129656 (knowledge-base)
- Wikidata label: Q145, revision 2554939741 (knowledge-base)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about AKL (United Kingdom).
- Canonical profile: https://brandsource.ai/brands/akl-united-kingdom
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/akl-united-kingdom/json-ld
- Citation profile API: https://brandsource.ai/api/brands/akl-united-kingdom/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
AKL identifies and synthesizes secondary metabolites of plant origin with proven efficacy & safety. This innovative approach greatly increases the chances of success, while reducing the probability of unexpected side effects. AKL is focused on developing its lead clinical asset APPA, a novel therapeutic for inflammatory diseases where there is a high unmet need, including osteoarthritis (OA) and other complex diseases of ageing.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.